Am J Cardiol:置入不同DES或改善支架内再狭窄患者预后

2013-12-04 高晓方 译 医学论坛网

美国一项研究表明,就药物洗脱支架内再狭窄(DES ISR)而言,采用与既往不同的药物洗脱支架置入有可能改善患者转归。论文11月25日在线发表于《美国心脏病学杂志》(Am J Cardiol)。 DES ISR可采用既往相同药物洗脱支架再置入(SS策略)或不同药物洗脱支架再置入(DS策略)加以治疗。此项荟萃分析利用对照试验和观察性研究对两种策略进行了

美国一项研究表明,就药物洗脱支架内再狭窄(DES ISR)而言,采用与既往不同的药物洗脱支架置入有可能改善患者转归。论文11月25日在线发表于《美国心脏病学杂志》(Am J Cardiol)。

DES ISR可采用既往相同药物洗脱支架再置入(SS策略)或不同药物洗脱支架再置入(DS策略)加以治疗。此项荟萃分析利用对照试验和观察性研究对两种策略进行了对比。主要转归为靶病变血运重建/靶血管血运重建(TLR/TVR),次要转归为严重不良心血管事件(MACE)、死亡和心梗。利用随机效应模型计算汇总比值比(OR)。

结果显示,共有包括1680例患者的10项研究符合纳入标准。纳入研究在任何终点方面均无显著异质性。DS策略可降低TLR/TVR(OR 0.73)以及MACE(OR 0.72)机率。在死亡和心梗发生率方面两种策略无显著差异。

原文出处:

Ankur Vyas, MDemail address, Marin Schweizer, PhD, Ashish Malhotra, MD, Wassef Karrowni, MD.Meta-analysis of Same versus Different Stent for Drug-Eluting Stent Restenosis.Am J Cardiol. 2013 Oct 2.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781655, encodeId=74e51e816551e, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 09 09:53:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691818, encodeId=4df11691818f7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 16 02:53:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985858, encodeId=17961985858fc, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Aug 10 11:53:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486175, encodeId=ffed14861e52c, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558488, encodeId=6e011558488e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564497, encodeId=a7d8156449e93, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781655, encodeId=74e51e816551e, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 09 09:53:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691818, encodeId=4df11691818f7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 16 02:53:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985858, encodeId=17961985858fc, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Aug 10 11:53:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486175, encodeId=ffed14861e52c, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558488, encodeId=6e011558488e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564497, encodeId=a7d8156449e93, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781655, encodeId=74e51e816551e, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 09 09:53:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691818, encodeId=4df11691818f7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 16 02:53:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985858, encodeId=17961985858fc, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Aug 10 11:53:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486175, encodeId=ffed14861e52c, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558488, encodeId=6e011558488e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564497, encodeId=a7d8156449e93, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781655, encodeId=74e51e816551e, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 09 09:53:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691818, encodeId=4df11691818f7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 16 02:53:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985858, encodeId=17961985858fc, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Aug 10 11:53:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486175, encodeId=ffed14861e52c, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558488, encodeId=6e011558488e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564497, encodeId=a7d8156449e93, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1781655, encodeId=74e51e816551e, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 09 09:53:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691818, encodeId=4df11691818f7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 16 02:53:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985858, encodeId=17961985858fc, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Aug 10 11:53:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486175, encodeId=ffed14861e52c, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558488, encodeId=6e011558488e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564497, encodeId=a7d8156449e93, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=)]
    2013-12-06 fusion
  6. [GetPortalCommentsPageByObjectIdResponse(id=1781655, encodeId=74e51e816551e, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 09 09:53:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691818, encodeId=4df11691818f7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri May 16 02:53:00 CST 2014, time=2014-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985858, encodeId=17961985858fc, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Aug 10 11:53:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486175, encodeId=ffed14861e52c, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558488, encodeId=6e011558488e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564497, encodeId=a7d8156449e93, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 06 01:53:00 CST 2013, time=2013-12-06, status=1, ipAttribution=)]
    2013-12-06 fusion

相关资讯

EHJ:新一代药物洗脱支架的安全性明显更优

1月9日,《欧洲心脏杂志》(European Heart Journal)在线发表了瑞典冠状动脉造影和血管成形术登记库(SCAAR)的研究论文。研究显示,与老一代的药物洗脱支架(DES)和裸金属支架(BMS)相比,新一代DES经皮冠状动脉介入治疗的再狭窄、支架内血栓形成和死亡风险明显较低。 瑞典乌普萨拉大学的Giovanna Sarno博士及其同事在未经选择的大规模真实世界人群中对不同类型的新型

JACC:重复置入支架治疗药物洗脱支架(DES)再狭窄有效

 《美国心脏病学会杂志》(J Am Coll Cardiol)杂志近期在线发表了韩国学者的一项前瞻性研究,证实对于药物洗脱支架(DES)内的局灶型再狭窄病变,重复置入西罗莫司洗脱支架(SES)较切割球囊血管成形术能更有效地降低晚期管腔丢失和随后的再狭窄率。而对于弥漫型DES再狭窄病变,置入SES或依维莫司洗脱支架(EES)在血管造影和临床转归方面疗效相当。   DES发生支架内再狭窄(ISR)

Heart:电话随访明显改善支架置入后患者服药依从性

  加拿大学者的一项研究表明,对药物洗脱支架(DES)置入后患者采取简单的4次电话回访可明显改善其1年的服药依从性,这一简单的干预方式也可显著改善双联抗血小板治疗(DAT)的持久性。相关论文2013年2月23日在线发表于《心脏》(heart)杂志。   该研究共纳入300例DES置入后的患者,将其随机分为干预组和对照组。为加强患者服药依从性,对干预组患者进行4次的电话随访,时间分别为DES

DES术后双联抗血小板治疗:何时停药?

药物洗脱支架(DES)的广泛应用显著降低了冠状动脉介入治疗(PCI)术后再狭窄率,但是,2006年前后发表的一系列临床研究和病理学研究均提示,第一代涂层不可降解DES的迟发支架血栓风险明显高于裸金属支架(BMS),因此国内外现行的指南均推荐在DES术后接受双联抗血小板治疗(DAPT)至少1年,除非病人存在出血高危因素。但长期DAPT是一柄双刃剑,在降低血栓风险的同时,不仅导致医疗费用的显著增高,而

置入DES后延长氯吡格雷治疗未降低SCVD风险

  最近,北京安贞医院的金泽宁在第10届中国介入心脏病学(CIT)大会最新临床试验与特色研究专场上公布的一项研究显示:药物洗脱支架(DES)置入后延长氯吡格雷的治疗时间(>12个月)对于严重心血管事件(死亡、心梗和卒中,SCVD)的风险降低似乎没有关系。   目前,欧洲指南推荐DES置入后氯吡格雷的使用时间是6~12个月,而最新美国心脏病学会/美国心脏学会/美国心血管影像与介入学会(ACC

EHJ:支架贴壁不良影响远期转归

  瑞士学者的一项研究表明,在长期随访期间,药物洗脱支架(DES)置入后支架贴壁不良(ISA)与心肌梗死和极晚期支架血栓形成发生率升高相关。论文于2012年1月26日在线发表于《欧洲心脏杂志》(Euro Heart J)。   DES置入后的晚期ISA较裸金属支架(BMS)置入后更为常见,并且与血管超敏反应和支架置入后血栓形成(ST)。此项研究对伴有221处病变的194例患者进行了为期5年的前瞻